Catalyst Capital Advisors LLC Reduces Position in Novo Nordisk A/S (NYSE:NVO)

Catalyst Capital Advisors LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 90.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 525 shares of the company's stock after selling 5,275 shares during the period. Catalyst Capital Advisors LLC's holdings in Novo Nordisk A/S were worth $36,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. M. Kulyk & Associates LLC lifted its position in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after buying an additional 119 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its holdings in Novo Nordisk A/S by 0.4% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 31,494 shares of the company's stock valued at $2,709,000 after purchasing an additional 136 shares in the last quarter. BIP Wealth LLC boosted its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock worth $313,000 after purchasing an additional 138 shares during the period. Xponance Inc. increased its stake in shares of Novo Nordisk A/S by 4.9% in the fourth quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after purchasing an additional 146 shares in the last quarter. Finally, Mystic Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 1.2% during the 4th quarter. Mystic Asset Management Inc. now owns 13,185 shares of the company's stock valued at $1,134,000 after purchasing an additional 150 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NVO shares. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded up $0.14 on Monday, reaching $69.31. The company's stock had a trading volume of 7,307,060 shares, compared to its average volume of 7,261,001. The stock's fifty day simple moving average is $69.96 and its 200-day simple moving average is $75.52. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $143.69. The company has a market capitalization of $309.47 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.